PT  - JOURNAL ARTICLE
AU  - Jeeban P Das
AU  - Hebert Alberto Vargas
AU  - Soleen Ghafoor
AU  - Alvin C Goh
AU  - Gary A Ulaner
TI  - Clinical utility of <sup>18</sup>F-FDG PET/CT in staging and treatment planning of urachal adenocarcinoma
AID  - 10.2967/jnumed.120.251561
DP  - 2020 Sep 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.120.251561
4099  - http://jnm.snmjournals.org/content/early/2020/09/18/jnumed.120.251561.short
4100  - http://jnm.snmjournals.org/content/early/2020/09/18/jnumed.120.251561.full
AB  - Purpose: Our objective was to evaluate the impact of utility of 18Fluorine (18F)-Fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) in the management of urachal adenocarcinoma (UrC-ADC). Methods: A retrospective analysis of patients with UrC-ADC from 2001-2019 at Memorial Sloan Kettering was performed. Mayo stage prior to 18F-FDG-PET/CT, rates of detection of the primary malignancy and metastases on 18F-FDG PET/CT, Mayo stage after 18F-FDG-PET/CT, and changes in patient management were determined. Results: Of 21 patients with UrC-ADC prior to 18F-FDG-PET/CT, Mayo staging was I/II in 8, III in 3 and IV in 10. 18F-FDG-PET/CT detected previously unidentified metastases in 8 of 21 (38%) patients, resulting in upstaging of disease in 3 (14%) patients, and a change in treatment in 4 patients (19%). Conclusion: 18F-FDG PET/CT has clinical utility in patients with UrC-ADC by identifying metastatic disease not appreciated on anatomic imaging, leading to changes in staging and patient management.